Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Sale of blood transfusion test unit boosts Novartis first-quarter profit

Published 24/04/2014, 06:41

ZURICH (Reuters) - Two days after announcing a radical overhaul of its structure, Novartis posted first-quarter profit that beat expectations boosted by an exceptional gain from the sale of its blood transfusion test unit.

The Swiss company said first-quarter net profit jumped 24 percent to $2.968 billion (1.768 billion pounds), beating the mean estimate of $2.7 billion in a Reuters poll. Net sales inched up 1 percent to $14.022 billion, compared to the average estimate of $14.246 billion.

The drugmaker's first-quarter results come two days after it announced deals worth over $25 billion to simplify its structure, strengthen its cancer portfolio and exit underperforming businesses.

(Reporting by Caroline Copley)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.